MRVI · Maravai LifeSciences Holdings
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $6.53
Note written ·
How this view changed
- · Rating raised from Low to Medium. Results, 4 November 2026: Q3 2026 revenue of $45.851M (+10.1% YoY) beat the $43.566M estimate cited by Benzinga, and full-year revenue guidance was raised to $212–216M and adjusted EBITDA guidance to $40–42M.
Price against the kill line
15.5% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $6.53, on record since 11 November 2026. The shares are up 32.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $6.53, the 13 October 2026 closing low and a level under the September low. A cut to the new $212–216M full-year revenue range, or TriLink growth under about 10% in the fourth quarter, would also break the case.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 45.9
- Revenue, change on a year (%)
- +10.1
- Gross margin (%)
- 35.3
- Operating margin (%)
- −45.0
- Net cash, cash less debt ($M)
- −74.2
- Enterprise value to sales (×)
- 5.6
All filed numbers
What Maravai LifeSciences Holdings reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 45.9 | +10.1 | 35.3 | −45.0 |
| first filed | 51.4 | +8.5 | 40.1 | −29.3 |
| first filed | 65.8 | +40.5 | 51.2 | −3.3 |
| first filed | 49.9 | −11.8 | 25.8 | −117.9 |
| first filed | 41.6 | −39.7 | 13.6 | −98.6 |
| first filed | 47.4 | −31.7 | 16.4 | −139.8 |
| Pre-tax income ($M) | −24.1 |
| Net income ($M) four quarters: −65.7 | −13.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +3.0 |
| Operating cash flow ($M) | −5.1 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 73.0 |
| Debt ($M) long-term debt | 147 |
| Net cash, cash less debt ($M) | −74.2 |
| Deferred revenue ($M) +84.6% on a year | 4.8 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 25.7 |
| Inventory ($M) | 43.2 |
| Shareholders' equity ($M) | 196 |
| Market value ($M) | 1,124 |
| Enterprise value, market value plus net debt ($M) | 1,198 |
| Enterprise value to sales (×) | 5.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 5.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 8.9% of shares outstanding sold short, 4.5 days of average trading to cover, −3.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $369K | $254K |
The thesis
Maravai LifeSciences supplies the materials used to make messenger RNA (mRNA) medicines. Its 4 November 2026 third-quarter report beat estimates and raised full-year guidance, so reported numbers now support the rise in the shares. The fourth-quarter report, expected around February 2027, decides whether the growth holds.
Revenue was $45.9 million, up 10.1% from $41.6 million a year earlier, according to the company's 8-K. Benzinga's headline put the consensus at $43.566 million. Full-year revenue guidance rose to $212.0–216.0 million from $205.0–215.0 million, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guidance rose to $40.0–42.0 million from $33.0–35.0 million.
The shares closed at $7.86 on 10 November 2026, below the $8.50 close of 28 October 2026 that preceded the report and 12.7% under the $9.00 52-week high. The story is well known: the revenue question was answered on 4 November 2026, and the shares have eased since the late-October high. Post-report analyst target changes were not found, so the last consensus target on record is MarketBeat's $7.38 from 13 October 2026.
Bullish and bearish views on Maravai LifeSciences Holdings, Inc.
The bull case on Maravai LifeSciences Holdings, Inc. (MRVI), in brief: third-quarter revenue beat. The bear case: net losses continue.
Bull case
- Third-quarter revenue beat. Revenue of $45.851 million beat the $43.566 million estimate cited by Benzinga, and the adjusted loss of $0.03 per share beat a $0.06 loss estimate. The company's 8-K shows growth of 10.1% year over year.
- Both units grew. TriLink, the nucleic-acid unit, grew 11.8% to $28.4 million. Cygnus, the biologics-safety testing unit, grew 7.5% to $17.5 million, up from 2.8% in the second quarter.
- Guidance rose at both lines. On 4 November 2026 the revenue range moved to $212–216 million from $205–215 million, against a $211.767 million estimate cited by Benzinga. CEO Bernd Brust tied the raise to third-quarter performance and fourth-quarter expectations.
- Profitability improved at the operating line. Adjusted EBITDA was $5.8 million in the third quarter, against a loss of $10.8 million in the third quarter of 2025, per the 8-K.
- Analyst coverage had already turned positive. TD Cowen assumed coverage on 5 October 2026 with a Buy rating and a $9.00 target, according to MarketBeat.
Bear case
- Net losses continue. The third-quarter GAAP net loss was $24.0 million, or $(0.09) per Class A share. Adjusted EBITDA is positive, but the GAAP line is not.
- The revenue raise is narrow. The low end of the range rose $7 million and the high end rose $1 million. The revised range sits only slightly above the $211.767 million estimate cited by Benzinga.
- Orders remain lumpy. The 8-K does not disclose cash or debt balances. Management's guidance excludes potential acquisitions, and the company has attributed earlier caution to the timing of large GMP and CDMO orders.
- The shares sit above the last recorded consensus target. The $7.86 close of 10 November 2026 is above MarketBeat's $7.38 consensus target of 13 October 2026, which ranged from Wells Fargo's $6.50 to TD Cowen's $9.00.
- The post-report move has been down. The shares closed at $8.50 on 28 October 2026 and at $7.86 on 10 November 2026, so buyers did not extend the late-October gain after the beat.
Price setup
The adjusted close was $7.86 on 10 November 2026, 12.7% below the $9.00 52-week high and 36.0% higher over three months. The 14-day relative strength index (RSI), a momentum gauge where readings above 70 are conventionally called overbought, was 52.5, down from 63.8 on 28 October 2026.
The 13 October 2026 closing low of $6.53 is the nearest downside reference; the shares closed at $7.07 on 15 October 2026. MarketBeat put the 200-day moving average at $5.66 on 13 October 2026. The $9.00 high is also the TD Cowen target and the top of the range of analyst targets recorded on 13 October 2026.
Crowding evidence is limited. The earnings date has passed, the RSI is mid-range, and no SEC Form 4 insider sales were found in this refresh.
Catalysts ahead
- November 2026 (dates not confirmed): Company-announced November 2026 investor conference appearances (announced 29 October 2026). Management commentary on fourth-quarter order timing and the Discovery-to-GMP pipeline could add detail to the raised guidance.
- ~February 2027 (est.): Fourth-quarter and full-year 2026 results. First test of the raised $212–216M revenue range and the $40–42M adjusted EBITDA range, plus any 2027 outlook.
What would change the view
A daily close below $6.53, the 13 October 2026 closing low and a level under the September low. A cut to the new $212–216M full-year revenue range, or TriLink growth under about 10% in the fourth quarter, would also break the case.
The risks this note tracks, each with what would confirm it:
- Fourth-quarter revenue falls short of what the raised guidance implies because large GMP or CDMO orders slip. Confirmed by: full-year revenue reported below the $212M low end of the range at the fourth-quarter report.
- Growth stays concentrated in TriLink while Cygnus slows from the 7.5% of the third quarter. Confirmed by: Cygnus growth below the 5–6% full-year pace in the company's framework, or TriLink growth under about 10% year over year.
- The shares give back the late-October gain even after the beat. Confirmed by: a daily close below $6.53, the 13 October 2026 closing low.
- The shares trade above the last consensus target recorded before the report, leaving less room if estimates do not rise. Confirmed by: post-report target changes that stay near MarketBeat's $7.38 consensus of 13 October 2026, or rating downgrades.
What it trades with
Maravai sells consumables and reagents to mRNA developers, so its revenue follows vaccine and therapeutic programme activity rather than a single customer. The 19 August 2026 gap higher came on another company's vaccine news, which shows the shares react to sector headlines. Small-cap life-science tools shares and the Nasdaq Biotechnology complex are the closest market references; no correlation figure was measured for this note.
The evidence, claim by claim (7)
- Q3 2026 revenue $45.9M (45,851K), +10.1% from $41.6M; TriLink $28.4M (+11.8%); Cygnus $17.5M (+7.5%). Maravai Q3 2026 results release (8-K Exhibit 99.1) · as of
- Q3 2026 GAAP net loss $(24.0)M, or $(0.09) per Class A share; adjusted EBITDA $5.8M versus $(10.8)M in Q3 2025; adjusted loss per share $(0.03). Maravai Q3 2026 results release (8-K Exhibit 99.1) · as of
- Full-year 2026 revenue guidance raised to $212.0–216.0M from $205.0–215.0M; adjusted EBITDA guidance raised to $40.0–42.0M from $33.0–35.0M. Maravai Q3 2026 results release (8-K Exhibit 99.1) · as of
- Third-quarter sales of $45.851M beat a $43.566M estimate and adjusted loss of $0.03 per share beat a $0.06 loss estimate; revised revenue guidance compares with a $211.767M estimate. Benzinga company news headlines · as of
- CEO Bernd Brust tied the raise to "our third-quarter performance and our expectations for the fourth quarter." Maravai Q3 2026 results release (8-K Exhibit 99.1) · as of
- Adjusted close $7.86; 52-week high $9.00; three-month change +36.0%; 14-day RSI 52.5. Split/dividend-adjusted daily closes · as of
- TD Cowen assumed coverage with a Buy rating and a $9.00 target; consensus target $7.38 (range $6.50–$9.00). MarketBeat, citing TD Cowen · as of
Sources